Published Year: 2017
Global Biologics Drug Discovery Market - Analysis and Forecast (2017-2025): (Focus on Method/Phase,
The global biologics drug discovery market was estimated to be $8.9 billion in 2016 and is...
Market Research Report
A quick peek into the report
Table of Contents
1.1 Biologics Drug Development
1.2 Biologics Drug Development: Key Trends
1.3 Integrated Discovery, Development, and commercialization of Biologics
1.4 Clinical Developmental Stages of Biologics
1.5 Manufacturing Stages of Biologics
1.6 Process Development
1.7 Bio Manufacturing Process
1.8 Formulation Development
1.9 Biologics In-House Drug Development Market
1.9.1 North America
1.9.2 Europe
1.9.3 Asia-Pacific
1.10 Biologics Outsourcing Drug Development Market
1.10.1 North America
1.10.2 Europe
1.10.3 Asia-Pacific
1.11 Biologics Drug Development Cost
2.1 Market Drivers
2.2 Market Restraints
2.3 Market Opportunities
3.1 Key Developmental Strategies
3.1.1 Acquisitions
3.1.2 Agreements, Partnership, Collaboration and Joint Ventures
3.1.3 Approvals
3.1.4. Clinical Study
3.1.5 Business Expansion
3.1.6 Product Launch
3.1.7 Awards
3.2 Porter’s Five Forces Analysis
4.1 Overview
4.1.1 Monoclonal Antibodies (mAbs)
4.1.2 Hormones
4.1.3 Growth Factors
4.1.4 Cytokines and Fusion Proteins
4.1.5 Therapeutic Enzymes
4.1.6 Blood Factors and Anticoagulants
4.1.7 Vaccines
5.1 Overview
5.1.1 In-House
5.1.2 Outsource
5.1.3 Pharma Excess
6.1 Overview
6.1.1 Clinical Manufacturing
6.1.1.1 Cell Bank Preparation and Cell Line Development
6.1.1.2 Cell Culture Upstream Development
6.1.1.3 Purification Downstream Development
6.1.2 Formulation Development
6.1.3 Bioassay Development
6.1.4 Analytical Services
7.1 Global Scenario
7.2 North America
7.2.1 The U.S.
7.2.2 Canada
7.3 Europe
7.3.1 The U.K.
7.3.2 Germany
7.3.3 France
7.3.4 Switzerland
7.3.5 Rest-of-Europe
7.4 Asia Pacific
7.4.1 Japan
7.4.2 China
7.4.3 South Korea
7.4.4 India
7.4.5 Rest-of-Asia-Pacific
7.5 Rest-of-the-World (RoW)
8.1 AbbVie Inc.
8.1.1 Abbvie Inc. : Overview
8.1.2 Abbvie Inc.: Overall Product Portfolio
8.1.2.1 Product Offerings for Global Biologics Drug Development Market
8.1.3 Financials
8.1.3.1 Financial Summary
8.1.4 SWOT Analysis
8.2 Allergan
8.2.1 Allergan Plc: Overview
8.2.2 Allergan Plc: Overall Product Portfolio
8.2.2.1 Product Offerings for Global Biologics Drug Development Market
8.2.3 Financials
8.2.3.1 Financial Summary
8.2.4 SWOT Analysis
8.3 Amgen, Inc.
8.3.1 Amgen, Inc.: Overview
8.3.2 Amgen, Inc.: Overall Product Portfolio
8.3.2.1 Product Offerings for Global Biologics Drug Development Market
8.3.3 Financials
8.3.3.1 Financial Summary
8.3.4 SWOT Analysis
8.4 Boehringer Ingelheim International GmbH
8.4.1 Boehringer Ingelheim International GmbH: Overview
8.4.2 Boehringer Ingelheim International GmbH: Overall Product Portfolio
8.4.2.1 Product Offerings for Global Biologics Drug Development Market
8.4.3 Financials
8.4.3.1 Financial Summary
8.4.4 SWOT Analysis
8.5 Catalent Inc.
8.5.1 Catalent Inc.: Overview
8.5.2 Catalent Inc.: Overall Product Portfolio
8.5.2.1 Product Offerings for Global Biologics Drug Development Market
8.5.3 Financials
8.5.3.1 Financial Summary
8.5.4 SWOT Analysis
8.6 Charles River Laboratories
8.6.1 Charles River Laboratories: Overview
8.6.2 Charles River Laboratories: Overall Product Portfolio
8.6.2.1 Product Offerings for Global Biologics Drug Development Market
8.6.3 Financials
8.6.3.1 Financial Summary
8.6.4 SWOT Analysis
8.7 FUJIFILM Diosynth Biotechnologies U.S.A., Inc
8.7.1 FUJIFILM Diosynth Biotechnologies U.S.A., Inc: Overview
8.7.2 FUJIFILM Holdings Corporation: Parent Company Overview
8.7.3 FUJIFILM Holdings Corporation: Overall Product Portfolio
8.7.3.1 Product Offerings for Global Biologics Drug Development Market
8.7.4 Financials
8.7.4.1 Financial Summary
8.7.5 SWOT Analysis
8.8 KBI Biopharma
8.8.1 KBI Biopharma: Overview
8.8.2 Corporate Summary
8.8.3 Product Offerings for Global Biologics Drug Development Market
8.8.4 SWOT Analysis
8.9 Lonza
8.9.1 Lonza: Overview
8.9.2 Lonza: Overall Product Portfolio
8.9.2.1 Product Offerings for Global Biologics Drug Development Market
8.9.3 Financials
8.9.3.1 Financial Summary
8.9.4 SWOT Analysis
8.10 MabPlex Inc.
8.10.1 MabPlex Inc.: Overview
8.10.2 Corporate Summary
8.10.3 Product Offerings for Global Biologics Drug Development Market
8.10.4 SWOT Analysis
8.11 Patheon
8.11.1 Patheon: Overview
8.11.2 Thermo Fisher Scientific, Inc.: Parent Company Overview
8.11.3 Thermo Fisher Scientific, Inc.: Overall Product Portfolio
8.11.3.1 Product Offerings for Global Biologics Drug Development Market
8.11.4 Thermo Fisher Scientific: Financials
8.11.4.1 Financial Summary
8.11.5 SWOT Analysis
8.12 Samsung BioLogics
8.12.1 Samsung BioLogics: Overview
8.12.2 Samsung BioLogics: Overall Product Portfolio
8.12.2.1 Product Offerings for Global Biologics Drug Development Market
8.12.3 Financials
8.12.3.1 Financial Summary
8.12.4 SWOT Analysis
8.13 SANOFI
8.13.1 SANOFI: Overview
8.13.2 SANOFI: Overall Product Portfolio
8.13.2.1 Product Offerings for Global Biologics Drug Development Market
8.13.3 Financials
8.13.3.1 Financial Summary
8.13.4 SWOT Analysis
8.14 Singota Solutions
8.14.1 Singota Solutions: Overview
8.14.2 Corporate Summary
8.14.3 Product Offerings for Global Biologics Drug Development Market
8.14.4 SWOT Analysis
8.15 WuXi Biologics
8.15.1 WuXi Biologics: Overview
8.15.2 WuXi Biologics: Overall Product Portfolio
8.15.2.1 Product Offerings for Global Biologics Drug Development Market
8.15.3 Financials
8.15.3.1 Financial Summary
8.15.4 SWOT Analysis
Table
of Contents
Global Biologics Drug Development Market
Focus on Facility, Service, Product Type, Country Analysis, and Market Dynamics - Analysis and Forecast, 2018-2027
Similar Product
You may also like
Published Year: 2017
Global Biologics Market - Analysis and Forecast (2017-2025): (Focus on Pipeline Analysis, Product Ty
The global biologics market generated a revenue of $238.8 billion in 2016. Introduction of...